Clearside Biomedical | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 201 M

Revenue: As of FY2025 Q3, the actual value is USD 201 M, beating the estimate of USD 88 K.

EPS: As of FY2025 Q3, the actual value is USD -1.14, missing the estimate of USD -0.525.

EBIT: As of FY2025 Q3, the actual value is USD -4.535 B.

License and other revenue for the three months ended September 30, 2025 was $0.2 million, compared to $1.0 million for the same period in 2024, reflecting a decrease of $0.8 million.
For the nine months ended September 30, 2025, license and other revenue was $3.0 million, compared to $1.4 million for the same period in 2024, reflecting an increase of $1.7 million.

Research and Development: Expenses decreased by $1.2 million from $4.1 million for the three months ended September 30, 2024 to $2.9 million for the same period in 2025. For the nine months ended September 30, 2025, expenses were $9.0 million, a decrease of $5.4 million from $14.3 million in the same period in 2024.
General and Administrative: Expenses increased by $1.5 million from $2.8 million for the three months ended September 30, 2024 to $4.3 million for the same period in 2025. For the nine months ended September 30, 2025, expenses were $9.6 million, an increase of $0.9 million from $8.7 million in the same period in 2024.

Loss from operations for the three months ended September 30, 2025 was $7.0 million, compared to $5.9 million for the same period in 2024.
For the nine months ended September 30, 2025, loss from operations was $15.8 million, compared to $21.7 million for the same period in 2024.

Operating Activities: Net cash used in operating activities for the nine months ended September 30, 2025 was $16.0 million, compared to $19.4 million for the same period in 2024.
Investing Activities: Net cash used in investing activities for the nine months ended September 30, 2025 was $9,000, compared to $9.9 million for the same period in 2024.
Financing Activities: Net cash provided by financing activities for the nine months ended September 30, 2025 was $2.8 million, compared to $14.3 million for the same period in 2024.

Clearside Biomedical, Inc. plans to explore strategic alternatives to advance its SCS platform and drug development pipeline, including potential sales, licenses, collaborations, partnerships, mergers, acquisitions, joint ventures, or other strategic transactions.
The company has paused all internal research and development programs during this strategic evaluation process and expects research and development expenses to decrease in future periods.
Based on current plans and forecasted expenses, the company does not believe its cash and cash equivalents will be able to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.